Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Paul E. Sax, Edwin DeJesus, Anthony Mills, +12

The Lancet

Hiv/aids CounsellingMedicineInitial TreatmentAntiviral Drug DevelopmentAntiviral Therapy +8

Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function

Polina German, Hui C. Liu, Javier Szwarcberg, +4

JAIDS Journal of Acquired Immune Deficiency Syndromes

A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection

Andrew Zolopa, Paul E. Sax, Edwin DeJesus, +10

JAIDS Journal of Acquired Immune Deficiency Syndromes

Serum CreatinineWeek 96Treatment And PreventionMedicineInitial Treatment +12

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy

Anthony Mills, Gordon Crofoot, Cheryl McDonald, +16

JAIDS Journal of Acquired Immune Deficiency Syndromes

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

Calvin Cohen, Richard Elion, Peter Ruane, +9

AIDS

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

Richard Elion, Calvin Cohen, Joseph Gathe, +7

AIDS

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

Chloe Orkin, Edwin DeJesus, Moti Ramgopal, +17

The Lancet HIV

Phase 3BTreatment And PreventionMedicineAntiviral Drug DevelopmentAntiviral Therapy +7

Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz

Vanessa Cooper, Graeme Moyle, Geraldine Reilly, +4

AIDS Care

Self-Assembled Biomimetic Superhydrophobic CaCO₃ Coating Inspired from Fouling Mineralization in Geothermal Water

Gong G. Wang, Li Zhu, Hui C. Liu, +1

Langmuir

EngineeringBiomimetic MaterialsSuper-hydrophobic SurfaceBio-based MaterialFouling +15

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide

Nicholas Funderburg, Grace A. McComsey, Manjusha Kulkarni, +12

EBioMedicine